DOCSLIB.ORG

Reference: WLI/100 31 January 2008

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Reference: WLI/100 31 January 2008 WORLD TRADE ORGANIZATION ORGANISATION MONDIALE DU COMMERCE ORGANIZACIÓN MUNDIAL DEL COMERCIO Reference: WLI/100 31 January 2008 MARRAKESH AGREEMENT ESTABLISHING THE WORLD TRADE ORGANIZATION DONE AT MARRAKESH ON 15 APRIL 1994 GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 CERTIFICATION OF MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII – JAPAN TRANSMISSION OF CERTIFIED TRUE COPY I have the honour to furnish herewith a certified true copy of the Certification of Modifications and Rectifications to Schedule XXXVIII – Japan, effective 22 January 2008. Pascal Lamy Director-General 08-0463 WT/Let/610 Centre William Rappard Rue de Lausanne 154 Case postale CH - 1211 Genève 21 Téléphone: (+41 22) 739 51 11 Fax: (+41 22) 731 42 06 Internet: http://www.wto.org SCHEDULES OF TARIFF CONCESSIONS TO THE GENERAL AGREEMENT ON TARIFFS AND TRADE 1994 CERTIFICATION OF MODIFICATIONS AND RECTIFICATIONS, 22 January 2008 SCHEDULE XXXVIII – JAPAN WHEREAS the CONTRACTING PARTIES to the General Agreement on Tariffs and Trade 1947 adopted, on 26 March 1980, a Decision on Procedures for Modification and Rectification of Schedules of Tariff Concessions (BISD 27S/25); WHEREAS in accordance with the provisions of the above-mentioned Decision, the draft containing modifications and rectifications to Schedule XXXVIII – Japan was communicated to all Members in documents G/MA/TAR/RS/136, G/MA/TAR/RS/136/Corr.1 and G/MA/TAR/RS/136/Corr.2 and was approved on 22 January 2008; IT IS HEREBY CERTIFIED that the modifications and rectifications to Schedule XXXVIII – Japan are established in conformity with the above-mentioned Decision. The annexed modifications and rectifications to the Schedule become effective in accordance with the notification given to that effect by the Government of Japan to the Director-General of the World Trade Organization (hereinafter referred to as the "WTO") upon completion of Japan's internal procedures. This Certification is deposited with the Director-General of the WTO, who shall promptly furnish a certified true copy thereof to each Member of the WTO. It shall be registered in accordance with the provisions of Article 102 of the Charter of the United Nations. DONE at Geneva this twenty second day of January, two thousand and eight. Pascal Lamy Certified copy: Director-General MODIFICATIONS AND RECTIFICATIONS TO SCHEDULE XXXVIII - JAPAN Page 3 WT/Let/610 SCHEDULE XXXVIII – JAPAN 22 January 2008 Page 4 WT/Let/610 PART I MOST-FAVOURED-NATION TARIFF SECTION I Agricultural Products Mark the tariff item number 3504.00 with a letter "P". SECTION II Other Products Mark the tariff item numbers 2903.30, 2903.47, 2907.30 and 2913.00 with a letter "P". Page 5 WT/Let/610 Attachment to SCHEDULE XXXVIII – JAPAN Replace “Annexes IA, IB and IC” in category (3) by “Annexes IA, IB, IC and ID”. Replace “Annexes IA, IB and IC” in category (4) by “Annexes IA, IB, IC and ID”, and “Annexes IIA, IIB and IIC” by “Annex II”. Replace “Annexes IVA, IVB and IVC” in category (6) by “Annexes IVA, IVB, IVC and IVD”. Page 6 WT/Let/610 Insert the following Annex after Annex IC Annex ID Designated Pharmaceutical Active Ingredients (Additions by the third review) HS Subheading Description HS Subheading Description 2842.90 vangatalcite 2903.47 perflubrodec 2843.90 eptaplatin 2906.19 becocalcidiol 2843.90 miriplatin 2906.19 inecalcitol 2843.90 padoporfin 2907.30 alfatradiol 2843.90 picoplatin 2909.49 atocalcitol 2843.90 satraplatin 2909.49 fispemifene 2843.90 triplatin tetranitrate 2909.49 ospemifene 2844.40 technetium (99m Tc) fanolesomab 2909.50 soneclosan 2844.40 technetium (99m Tc) nitridocade 2914.40 irofulven 2844.40 yttrium (90 Y) tacatuzumab tetraxetan 2914.70 nebicapone 2845.90 deutolperisone 2915.39 anecortave 2846.90 gadocoletic acid 2915.90 arundic acid 2846.90 gadodenterate 2916.39 bexarotene 2846.90 gadofosveset 2918.19 icomucret 2846.90 gadomelitol 2918.19 tenivastatin 2903.30 perflexane 2918.19 tisocalcitate 2903.30 perflisobutane 2918.90 etalocib 2903.30 perflubutane 2918.90 gemcabene 2903.30 perflutren 2918.90 naveglitazar Page 7 WT/Let/610 HS Subheading Description HS Subheading Description 2918.90 tesaglitazar 2922.50 caloxetic acid 2918.90 travoprost 2922.50 desvenlafaxine 2921.30 neramexane 2922.50 etilevodopa 2921.49 cinacalcet 2922.50 fesoterodine 2921.49 delucemine 2922.50 fosveset 2921.49 levmetamfetamine 2922.50 isalmadol 2922.19 edronocaine 2922.50 melevodopa 2922.19 esoxybutynin 2922.50 ritobegron 2922.19 fingolimod 2922.50 solabegron 2922.19 mantabegron 2924.10 carglumic acid 2922.19 squalamine 2924.10 teglicar 2922.19 talibegron 2924.10 valrocemide 2922.19 tesmilifene 2924.29 aliskiren 2922.19 trodusquemine 2924.29 amiglumide 2922.19 xidecaflur 2924.29 arformoterol 2922.29 nolomirole 2924.29 axitirome 2922.29 tapentadol 2924.29 efaproxiral 2922.29 tecalcet 2924.29 frakefamide 2922.30 esketamine 2924.29 iosimenol 2922.49 eglumetad 2924.29 lacosamide 2922.49 icofungipen 2924.29 ladostigil 2922.49 lumiracoxib 2924.29 neboglamine 2922.49 robenacoxib 2924.29 oseltamivir 2922.50 axomadol 2924.29 ralfinamide Page 8 WT/Let/610 HS Subheading Description HS Subheading Description 2924.29 safinamide 2929.90 avasimibe 2924.29 salcaprozic acid 2929.90 banoxantrone 2924.29 salclobuzic acid 2929.90 disufenton sodium 2924.29 tabimorelin 2930.90 armodafinil 2924.29 tacedinaline 2930.90 canfosfamide 2924.29 talaglumetad 2930.90 desmeninol 2924.29 taltobulin 2930.90 dextiopronin 2924.29 topilutamide 2930.90 eflucimibe 2924.29 valategrast 2930.90 esonarimod 2925.20 amelubant 2930.90 exisulind 2925.20 anisperimus 2930.90 pemaglitazar 2925.20 delmitide 2930.90 rimeporide 2925.20 olanexidine 2930.90 tanomastat 2925.20 peramivir 2931.00 ibrolipim 2926.90 cilomilast 2931.00 lidadronic acid 2926.90 manitimus 2932.19 milataxel 2926.90 naminidil 2932.19 rostafuroxin 2926.90 teriflunomide 2932.29 alemcinal 2928.00 eplivanserin 2932.29 amotosalen 2928.00 istaroxime 2932.29 ascorbyl gamolenate 2928.00 marimastat 2932.29 disermolide 2928.00 meldonium 2932.29 firocoxib 2928.00 sardomozide 2932.29 fluorescein lisicol 2928.00 semapimod 2932.29 mitemcinal Page 9 WT/Let/610 HS Subheading Description HS Subheading Description 2932.29 rofecoxib 2933.29 dapiclermine 2932.29 selamectin 2933.29 dibotermin alfa 2932.99 artemotil 2933.29 doranidazole 2932.99 artenimol 2933.29 emfilermin 2932.99 carabersat 2933.29 enfuvirtide 2932.99 defoslimod 2933.29 eptotermin alfa 2932.99 dexbudesonide 2933.29 exenatide 2932.99 enrasentan 2933.29 fadolmidine 2932.99 escitalopram 2933.29 fampronil 2932.99 fondaparinux sodium 2933.29 fipamezole 2932.99 idraparinux sodium 2933.29 imidafenacin 2932.99 idronoxil 2933.29 lusupultide 2932.99 lirimilast 2933.29 mecasermin rinfabate 2932.99 omigapil 2933.29 olmesartan 2932.99 ortataxel 2933.29 palifermin 2932.99 osemozotan 2933.29 rebimastat 2932.99 oxeglitazar 2933.29 repifermin 2932.99 paclitaxel ceribate 2933.29 semparatide 2932.99 ramelteon 2933.29 tadekinig alfa 2932.99 tidembersat 2933.29 tiplimotide 2932.99 tonabersat 2933.39 adekalant 2933.29 abrineurin 2933.39 alvameline 2933.29 bifarcept 2933.39 alvimopan 2933.29 cipralisant 2933.39 ancriviroc Page 10 WT/Let/610 HS Subheading Description HS Subheading Description 2933.39 arimoclomol 2933.39 iferanserin 2933.39 atazanavir 2933.39 ilaprazole 2933.39 bamirastine 2933.39 indibulin 2933.39 barixibat 2933.39 ipravacaine 2933.39 bilastine 2933.39 ispronicline 2933.39 capravirine 2933.39 itriglumide 2933.39 caricotamide 2933.39 iturelix 2933.39 cipemastat 2933.39 lanicemine 2933.39 crobenetine 2933.39 levolansoprazole 2933.39 dabigatran 2933.39 lonafarnib 2933.39 dabigatran etexilate 2933.39 maraviroc 2933.39 dersalazine 2933.39 maropitant 2933.39 desloratadine 2933.39 miglustat 2933.39 dexlansoprazole 2933.39 minopafant 2933.39 dexmethylphenidate 2933.39 nerispirdine 2933.39 ecalcidene 2933.39 otamixaban 2933.39 elarofiban 2933.39 paliroden 2933.39 enzastaurin 2933.39 pipendoxifene 2933.39 esomeprazole 2933.39 prazarelix 2933.39 etoricoxib 2933.39 rimonabant 2933.39 ezlopitant 2933.39 rivanicline 2933.39 fidexaban 2933.39 senazodan 2933.39 gimeracil 2933.39 solimastat 2933.39 icaridin 2933.39 sorafenib Page 11 WT/Let/610 HS Subheading Description HS Subheading Description 2933.39 surinabant 2933.40 solifenacin 2933.39 tebanicline 2933.40 tafenoquine 2933.39 tecastemizole 2933.40 talnetant 2933.39 tenatoprazole 2933.40 tariquidar 2933.39 tesofensine 2933.40 torcetrapib 2933.39 ticalopride 2933.40 zelandopam 2933.39 timcodar 2933.40 zoniporide 2933.39 traxoprodil 2933.59 alamifovir 2933.39 varenicline 2933.59 albaconazole 2933.39 vatalanib 2933.59 ambrisentan 2933.39 vofopitant 2933.59 avanafil 2933.39 zanapezil 2933.59 balicatib 2933.40 alilusem 2933.59 cadrofloxacin 2933.40 gantacurium chloride 2933.59 caldaret 2933.40 garenoxacin 2933.59 dapivirine 2933.40 laniquidar 2933.59 darusentan 2933.40 meclinertant 2933.59 dasantafil 2933.40 olamufloxacin 2933.59 degarelix 2933.40 palosuran 2933.59 detiviciclovir 2933.40 pelitinib 2933.59 dofequidar 2933.40 pinokalant 2933.59 donitriptan 2933.40 pitavastatin 2933.59 emivirine 2933.40 pradofloxacin 2933.59 enecadin 2933.40 sitamaquine 2933.59 entecavir Page 12 WT/Let/610 HS Subheading Description HS Subheading Description 2933.59 erlotinib 2933.59 seliciclib 2933.59 esmirtazapine 2933.59 tandutinib 2933.59 etravirine 2933.59 tenofovir 2933.59 etriciguat 2933.59 tiviciclovir 2933.59 falnidamol 2933.59 valomaciclovir 2933.59 feloprentan 2933.59 vandetanib 2933.59 figopitant 2933.59 vestipitant 2933.59 forodesine 2933.59 zonampanel 2933.59 imatinib 2933.59
Load more

Recommended publications
  • E30 SEM. O.C. Disclosed Is a Compound Represented by the Formula (1) (51) Int
    USOO9453000B2 (12) United States Patent (10) Patent No.: US 9.453,000 B2 Kimura et al. (45) Date of Patent: *Sep. 27, 2016 (54) POLYCYCLIC COMPOUND (56) References Cited (75) Inventors: Teiji Kimura, Tsukuba (JP); Noritaka U.S. PATENT DOCUMENTS Kitazawa, Tsukuba (JP); Toshihiko 3,470,167 A 9, 1969 Sarkar Kaneko, Tsukuba (JP); Nobuaki Sato, 3,989,816 A 1 1/1976 Rajadhyaksha Tsukuba (JP); Koki Kawano, Tsukuba 4,910,200 A 3, 1990 Curtze et al. (JP): Koichi Ito, Tsukuba (JP); 5,281,626 A 1/1994 Oinuma et al. M s Tak ishi Tsukub JP 5,563,162 A 10, 1996 Oku et al. amoru Takaishi Tsukuba (JP); 5,804,577 A 9, 1998 Hebeisen et al. Takeo Sasaki, Tsukuba (JP); Yu 5,985,856 A 11/1999 Stella et al. Yoshida, Tsukuba (JP); Toshiyuki 6,235,728 B1 5, 2001 Golik et al. Uemura, Tsukuba (JP); Takashi Doko, g R 1939. E. al. Its SE E. Shinmyo, 7,138.414 B2 11/2006 Schoenafingereatch et al. et al. sukuba (JP); Daiju Hasegawa, 7,300,936 B2 11/2007 Parker et al. Tsukuba (JP); Takehiko Miyagawa, 7,314,940 B2 1/2008 Graczyk et al. Hatfield (GB); Hiroaki Hagiwara, 7,618,960 B2 11/2009 Kimura et al. Tsukuba (JP) 7,667,041 B2 2/2010 Kimura et al. 7,687,640 B2 3/2010 Kimura et al. 7,713,993 B2 5/2010 Kimura et al. (73) Assignee: EISAI R&D MANAGEMENT CO., 7,737,141 B2 6/2010 Kimura et al. LTD., Tokyo (JP) 7,880,009 B2 2/2011 Kimura et al.
    [Show full text]
  • PRODUCT INFORMATION ABT-594 Item No
    PRODUCT INFORMATION ABT-594 Item No. 22822 CAS Registry No.: 203564-54-9 Formal Name: 5-[(2R)-2-azetidinylmethoxy]-2- H chloro-pyridine, monohydrochloride N Synonyms: Ebanicline, Tebanicline O MF: C9H11ClN2O • HCl FW: 235.1 N Purity: ≥95% Cl Supplied as: A solid • HCl Storage: -20°C Stability: ≥2 years Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis. Laboratory Procedures ABT-594 is supplied as a solid. A stock solution may be made by dissolving the ABT-594 in the solvent of choice. ABT-594 is soluble in the organic solvent DMSO, which should be purged with an inert gas. Description ABT-594 is a potent agonist of neuronal α4β2 subunit-containing nicotinic acetylcholine receptors 1 (nAChRs; Ki = 37 pM in a radioligand binding assay). It is selective for neuronal nAChRs over neuromuscular α1β1δγ subunit-containing nAChRs (Ki = 10,000 nM), α1B-, α2B-, and α2C-adrenergic receptors (Kis = 890, 597, and 342 nM, respectively), and 70 other receptors, enzymes, and transporters 86 + (Kis = >1,000 nM) in radioligand binding assays. ABT-594 induces [ Rb ] efflux in K177 cells transfected with human neuronal α4β2 subunit-containing nAChRs (EC50 = 140 nM). In vivo, ABT-594 (0.05 and 0.01 mg/kg, s.c.) increases latency to paw withdrawal in a hot-plate test in rats.2 It also induces hypothermia, seizures, and an increase in blood pressure. References 1. Donnelly-Roberts, D.L., Puttfarcken, P.S., Kuntzweiler, T.A., et al. ABT-594 [(R)-5-(2-azetidinylmethoxy)- 2-chloropyridine]: A novel, orally effective analgesic acting via neuronal nicotinic acetylcholine receptors: I.
    [Show full text]
  • WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T
    (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (10) International Publication Number (43) International Publication Date WO 2017/145013 Al 31 August 2017 (31.08.2017) P O P C T (51) International Patent Classification: (81) Designated States (unless otherwise indicated, for every C07D 498/04 (2006.01) A61K 31/5365 (2006.01) kind of national protection available): AE, AG, AL, AM, C07D 519/00 (2006.01) A61P 25/00 (2006.01) AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, (21) Number: International Application DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, PCT/IB20 17/050844 HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KH, KN, (22) International Filing Date: KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, 15 February 2017 (15.02.2017) MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, (25) Filing Language: English RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, (26) Publication Language: English TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (30) Priority Data: 62/298,657 23 February 2016 (23.02.2016) US (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, (71) Applicant: PFIZER INC. [US/US]; 235 East 42nd Street, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, New York, New York 10017 (US).
    [Show full text]
  • Nitrate Prodrugs Able to Release Nitric Oxide in a Controlled and Selective
    Europäisches Patentamt *EP001336602A1* (19) European Patent Office Office européen des brevets (11) EP 1 336 602 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.7: C07C 205/00, A61K 31/00 20.08.2003 Bulletin 2003/34 (21) Application number: 02425075.5 (22) Date of filing: 13.02.2002 (84) Designated Contracting States: (71) Applicant: Scaramuzzino, Giovanni AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU 20052 Monza (Milano) (IT) MC NL PT SE TR Designated Extension States: (72) Inventor: Scaramuzzino, Giovanni AL LT LV MK RO SI 20052 Monza (Milano) (IT) (54) Nitrate prodrugs able to release nitric oxide in a controlled and selective way and their use for prevention and treatment of inflammatory, ischemic and proliferative diseases (57) New pharmaceutical compounds of general effects and for this reason they are useful for the prep- formula (I): F-(X)q where q is an integer from 1 to 5, pref- aration of medicines for prevention and treatment of in- erably 1; -F is chosen among drugs described in the text, flammatory, ischemic, degenerative and proliferative -X is chosen among 4 groups -M, -T, -V and -Y as de- diseases of musculoskeletal, tegumental, respiratory, scribed in the text. gastrointestinal, genito-urinary and central nervous sys- The compounds of general formula (I) are nitrate tems. prodrugs which can release nitric oxide in vivo in a con- trolled and selective way and without hypotensive side EP 1 336 602 A1 Printed by Jouve, 75001 PARIS (FR) EP 1 336 602 A1 Description [0001] The present invention relates to new nitrate prodrugs which can release nitric oxide in vivo in a controlled and selective way and without the side effects typical of nitrate vasodilators drugs.
    [Show full text]
  • (19) United States (12) Patent Application Publication (10) Pub
    US 20130289061A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2013/0289061 A1 Bhide et al. (43) Pub. Date: Oct. 31, 2013 (54) METHODS AND COMPOSITIONS TO Publication Classi?cation PREVENT ADDICTION (51) Int. Cl. (71) Applicant: The General Hospital Corporation, A61K 31/485 (2006-01) Boston’ MA (Us) A61K 31/4458 (2006.01) (52) U.S. Cl. (72) Inventors: Pradeep G. Bhide; Peabody, MA (US); CPC """"" " A61K31/485 (201301); ‘4161223011? Jmm‘“ Zhu’ Ansm’ MA. (Us); USPC ......... .. 514/282; 514/317; 514/654; 514/618; Thomas J. Spencer; Carhsle; MA (US); 514/279 Joseph Biederman; Brookline; MA (Us) (57) ABSTRACT Disclosed herein is a method of reducing or preventing the development of aversion to a CNS stimulant in a subject (21) App1_ NO_; 13/924,815 comprising; administering a therapeutic amount of the neu rological stimulant and administering an antagonist of the kappa opioid receptor; to thereby reduce or prevent the devel - . opment of aversion to the CNS stimulant in the subject. Also (22) Flled' Jun‘ 24’ 2013 disclosed is a method of reducing or preventing the develop ment of addiction to a CNS stimulant in a subj ect; comprising; _ _ administering the CNS stimulant and administering a mu Related U‘s‘ Apphcatlon Data opioid receptor antagonist to thereby reduce or prevent the (63) Continuation of application NO 13/389,959, ?led on development of addiction to the CNS stimulant in the subject. Apt 27’ 2012’ ?led as application NO_ PCT/US2010/ Also disclosed are pharmaceutical compositions comprising 045486 on Aug' 13 2010' a central nervous system stimulant and an opioid receptor ’ antagonist.
    [Show full text]
  • University of Florida Thesis Or Dissertation Formatting
    THE PROTECTIVE EFFECTS OF PLASMA GELSOLIN AND ALPHA 1-ANTITRYPSIN ON ISCHEMIC STROKE OUTCOME IN RATS By HUONG LE MOLDTHAN A DISSERTATION PRESENTED TO THE GRADUATE SCHOOL OF THE UNIVERSITY OF FLORIDA IN PARTIAL FULFILLMENT OF THE REQUIREMENTS FOR THE DEGREE OF DOCTOR OF PHILOSOPHY UNIVERSITY OF FLORIDA 2012 1 © 2012 Huong Le Moldthan 2 To my beloved grandmother, parents and husband, Matthew Michael Moldthan 3 ACKNOWLEDGMENTS Obtaining my doctorate has been the most challenging goal of my life so far. Yet, starting is the best decision that I will never regret. During the journey to this dissertation, both figurative as well as literal, I am deeply indebted to the many people who have provided me inspiration and supported my studies. My greatest gratitude goes to Dr. Jeffrey Hughes, my former mentor who gave me an opportunity to do research in his lab and for his excellent supervision, as well as his great sense of humor. I would like to gratefully thank Dr. Sihong Song for continuing to guide me in a new project when Dr. Hughes left. I also would like to express my thanks to Dr. Michael King and other committee members, Dr. Christopher Batich and Dr. Guenther Hochhaus for their detailed comments and great suggestions. Without their guidance, I would not have had such a great experience in completing this challenging project. I would like to express my special thanks to Dr. Aaron Hirko, for his constant help, patience and invaluable advice. A sincere thank you goes to Jeffrey Thinschmidt, who was always willing to help me with handling animals, performing laser-Doppler imaging experiments, providing great comments on dissertation as well as my talks, and contributing to a very happy lab environment.
    [Show full text]
  • Tanibirumab (CUI C3490677) Add to Cart
    5/17/2018 NCI Metathesaurus Contains Exact Match Begins With Name Code Property Relationship Source ALL Advanced Search NCIm Version: 201706 Version 2.8 (using LexEVS 6.5) Home | NCIt Hierarchy | Sources | Help Suggest changes to this concept Tanibirumab (CUI C3490677) Add to Cart Table of Contents Terms & Properties Synonym Details Relationships By Source Terms & Properties Concept Unique Identifier (CUI): C3490677 NCI Thesaurus Code: C102877 (see NCI Thesaurus info) Semantic Type: Immunologic Factor Semantic Type: Amino Acid, Peptide, or Protein Semantic Type: Pharmacologic Substance NCIt Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor tyrosine kinase expressed by endothelial cells, while VEGF is overexpressed in many tumors and is correlated to tumor progression. PDQ Definition: A fully human monoclonal antibody targeting the vascular endothelial growth factor receptor 2 (VEGFR2), with potential antiangiogenic activity. Upon administration, tanibirumab specifically binds to VEGFR2, thereby preventing the binding of its ligand VEGF. This may result in the inhibition of tumor angiogenesis and a decrease in tumor nutrient supply. VEGFR2 is a pro-angiogenic growth factor receptor
    [Show full text]
  • (12) United States Patent (10) Patent No.: US 7,723,342 B2 Palani Et Al
    US007723342B2 (12) United States Patent (10) Patent No.: US 7,723,342 B2 Palani et al. (45) Date of Patent: *May 25, 2010 (54) HETEROCYCLES AS NICOTINIC ACID FOREIGN PATENT DOCUMENTS RECEPTORAGONSTS FOR THE TREATMENT OF DYSLIPIDEMA DE 263 891 A3 1, 1989 DE 265 760 A3 3, 1989 (75) Inventors: Anandan Palani, Bridgewater, NJ (US); FR 256223 * 10, 1985 Jing Su, Scotch Plains, NJ (US); Dong WO WOOO698.29 A1 11, 2000 WO WO 02/084.298 A2 10, 2002 Xiao, Warren, NJ (US); Xianhai Huang, WO WO 2004037159 * 10/2003 Warren, NJ (US); Ashwin U. Rao, WO WO 2004/O37159 A2 5, 2004 Avenel, NJ (US); Xiao Chen, Edison, NJ WO WO 2004/047755 A2 6, 2004 (US); Haiqun Tang, Belle Mead, NJ WO WO 2004/083388 A2 9, 2004 (US); Jun Qin, Edison, NJ (US); Ying WO WO 2004f1 10368 A2 12/2004 Huang, Berkeley Heights, NJ (US); WO WO 2004f1 10375 A2 12/2004 Robert G. Aslanian, Rockaway, NJ WO WO 2005/OOO217 A2 1, 2005 (US); Brian A. McKittrick, New WO WO 2006O78834 * 1 2005 Vernon, NJ (US) WO WO 2005, O7795O A2 8, 2005 WO WO 2005,105097 A2 11/2005 (73) Assignee: Schering Corporation, Kenilworth, NJ WO WO 2006/045564 A1 5, 2006 (US) WO WO 2006/045565 A1 5, 2006 Notice: WO WO 2006/078834 A1 T 2006 (*) Subject to any disclaimer, the term of this WO WO 2006/089009 A2 8, 2006 patent is extended or adjusted under 35 WO WO 2006/092430 A1 9, 2006 U.S.C. 154(b) by 10 days.
    [Show full text]
  • Modifications to the Harmonized Tariff Schedule of the United States To
    U.S. International Trade Commission COMMISSIONERS Shara L. Aranoff, Chairman Daniel R. Pearson, Vice Chairman Deanna Tanner Okun Charlotte R. Lane Irving A. Williamson Dean A. Pinkert Address all communications to Secretary to the Commission United States International Trade Commission Washington, DC 20436 U.S. International Trade Commission Washington, DC 20436 www.usitc.gov Modifications to the Harmonized Tariff Schedule of the United States to Implement the Dominican Republic- Central America-United States Free Trade Agreement With Respect to Costa Rica Publication 4038 December 2008 (This page is intentionally blank) Pursuant to the letter of request from the United States Trade Representative of December 18, 2008, set forth in the Appendix hereto, and pursuant to section 1207(a) of the Omnibus Trade and Competitiveness Act, the Commission is publishing the following modifications to the Harmonized Tariff Schedule of the United States (HTS) to implement the Dominican Republic- Central America-United States Free Trade Agreement, as approved in the Dominican Republic-Central America- United States Free Trade Agreement Implementation Act, with respect to Costa Rica. (This page is intentionally blank) Annex I Effective with respect to goods that are entered, or withdrawn from warehouse for consumption, on or after January 1, 2009, the Harmonized Tariff Schedule of the United States (HTS) is modified as provided herein, with bracketed matter included to assist in the understanding of proclaimed modifications. The following supersedes matter now in the HTS. (1). General note 4 is modified as follows: (a). by deleting from subdivision (a) the following country from the enumeration of independent beneficiary developing countries: Costa Rica (b).
    [Show full text]
  • (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest Et A1
    US007964607B2 (12) United States Patent (10) Patent N0.: US 7,964,607 B2 Verhoest et a1. (45) Date of Patent: Jun. 21, 2011 (54) PYRAZOLO[3,4-D]PYRIMIDINE FOREIGN PATENT DOCUMENTS COMPOUNDS EP 1460077 9/2004 WO 02085904 10/2002 (75) Inventors: Patrick Robert Verhoest, Old Lyme, CT WO 2004037176 5/2004 (US); Caroline ProulX-Lafrance, Ledyard, CT (US) OTHER PUBLICATIONS Wunder et a1, M01. PharmacoL, v01. 28, N0. 6, (2005), pp. 1776 (73) Assignee: P?zer Inc., New York, NY (U S) 1781. van der Staay et a1, Neuropharmacology, v01. 55 (2008), pp. 908 ( * ) Notice: Subject to any disclaimer, the term of this 918. patent is extended or adjusted under 35 USC 154(b) by 562 days. Primary Examiner * Susanna Moore (74) Attorney, Agent, or Firm * Jennifer A. Kispert; (21) Appl.No.: 12/118,062 Michael Herman (22) Filed: May 9, 2008 (57) ABSTRACT (65) Prior Publication Data The invention provides PDE9-inhibiting compounds of For US 2009/0030003 A1 Jan. 29, 2009 mula (I), Related US. Application Data (60) Provisional application No. 60/917,333, ?led on May 11, 2007. (51) Int. Cl. C07D 48 7/04 (2006.01) A61K 31/519 (2006.01) A61P 25/28 (2006.01) (52) US. Cl. ................................... .. 514/262.1; 544/262 (58) Field of Classi?cation Search ................ .. 544/262; 5 1 4/2 62 .1 See application ?le for complete search history. and pharmaceutically acceptable salts thereof, Wherein R, R1, (56) References Cited R2 and R3 are as de?ned herein. Pharmaceutical compositions containing the compounds of Formula I, and uses thereof in U.S.
    [Show full text]
  • G Protein-Coupled Receptors
    S.P.H. Alexander et al. The Concise Guide to PHARMACOLOGY 2015/16: G protein-coupled receptors. British Journal of Pharmacology (2015) 172, 5744–5869 THE CONCISE GUIDE TO PHARMACOLOGY 2015/16: G protein-coupled receptors Stephen PH Alexander1, Anthony P Davenport2, Eamonn Kelly3, Neil Marrion3, John A Peters4, Helen E Benson5, Elena Faccenda5, Adam J Pawson5, Joanna L Sharman5, Christopher Southan5, Jamie A Davies5 and CGTP Collaborators 1School of Biomedical Sciences, University of Nottingham Medical School, Nottingham, NG7 2UH, UK, 2Clinical Pharmacology Unit, University of Cambridge, Cambridge, CB2 0QQ, UK, 3School of Physiology and Pharmacology, University of Bristol, Bristol, BS8 1TD, UK, 4Neuroscience Division, Medical Education Institute, Ninewells Hospital and Medical School, University of Dundee, Dundee, DD1 9SY, UK, 5Centre for Integrative Physiology, University of Edinburgh, Edinburgh, EH8 9XD, UK Abstract The Concise Guide to PHARMACOLOGY 2015/16 provides concise overviews of the key properties of over 1750 human drug targets with their pharmacology, plus links to an open access knowledgebase of drug targets and their ligands (www.guidetopharmacology.org), which provides more detailed views of target and ligand properties. The full contents can be found at http://onlinelibrary.wiley.com/doi/ 10.1111/bph.13348/full. G protein-coupled receptors are one of the eight major pharmacological targets into which the Guide is divided, with the others being: ligand-gated ion channels, voltage-gated ion channels, other ion channels, nuclear hormone receptors, catalytic receptors, enzymes and transporters. These are presented with nomenclature guidance and summary information on the best available pharmacological tools, alongside key references and suggestions for further reading.
    [Show full text]
  • Axon Medchem
    Understanding Communication Satisfaction “Together we are stronger!” Axon Medchem - A top-line chemistry service platform specialized in contract research in medicinal chemistry and Contract Research Organization high-quality synthesis of bio-active and/or drug-like molecules. in Medicinal Chemistry Providing Axon Ligands™ for Pharmaceutical Research - Proven track record in developing novel drug candidates and achieving excellence for a decade by collaborating with partners and serving research scientists all over the world. Prime Source High Value - Prime source of highest performance and up-to-date life science reagents, providing Axon High Quality Ligands™ for advanced pharmaceutical research. Axon Ligands™ - Reagents for over 500 Biological Targets - A unique collection of biologically active molecules, as world-wide recognized research tools and drug standards in diversified application fields such as neurological disorders, cardiovascular Axon Medchem BV The Netherlands disease, pain and inflammation, epigenetics, stem cell biology, apoptosis and many more on cell Tel: +31-50-3118007 signaling and oncology research. Fax: +31-50-3600390 [email protected] - Featured products with our expertise including CNS reagents, ion channel modulators, signal transduction regulators (such as kinase inhibitors) and much more … Axon Medchem LLC USA Axon Ligands™ are widely used by research institutes and Axon Medchem has been cited in Tel: (888) 703-9861 numerous publications as their supplier of drugs. Fax: (703) 596-8062 [email protected]
    [Show full text]